Only one RA derivative, the acyclic retinoid with a prolonged half-life, has been used to treat recurrent HCV-related solid liver cancer after curative therapy by targeting oncogenic MYCN, which transcriptionally regulates EPCAM, a biomarker of HCC CSCs [24], in addition to RAR-RXR [13, 25, 26]. The gene discussed is RARA; the disease is hepatocellular carcinoma.